BioShares Biotechnology Financial Ratios

BioShares Biotechnology Clinical Trials -- USA Etf  

USD 29.85  1.1  3.55%

Use fundamental data analysis to double-check all available reported financial drivers of BioShares Biotechnology to find out if markets are presently mispricing the etf. We found ten available fundamental indicators for BioShares Biotechnology Clinical Trials which can be compared to its rivals. Please makes use of BioShares Biotechnology Number of Employees as well as the relationship between One Year Return and Net Asset to make a decision on weather BioShares Biotechnology is priced fairly. Use BioShares Biotechnology to protect against small markets fluctuations. The etf experiences unexpected downward movement. The market is reacting to new fundamentals. Check odds of BioShares Biotechnology to be traded at $28.66 in 30 days

BioShares Biotechnology Company Summary

BioShares Biotechnology competes with Health Care, iShares Nasdaq, Vanguard Health, SPDR SP, and ISHARE DJ. The investment seeks investment results that correspond, before fees and expenses, to the price and yield performance of the LifeSci Biotechnology Clinical Trials Index. Under normal market conditions, the fund will invest not less than 80 percent of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval. The fund is non-diversified.

BioShares Biotechnology Price to Earning vs Price to Book

BioShares Biotechnology Clinical Trials is second largest ETF in price to earning as compared to similar ETFs. It is rated below average in price to book as compared to similar ETFs fabricating about  0.04  of Price to Book per Price to Earning. The ratio of Price to Earning to Price to Book for BioShares Biotechnology Clinical Trials is roughly  22.78 

BioShares Biotechnology Systematic Risk

The output start index for this execution was six with a total number of output elements of eleven. The Beta measures systematic risk based on how returns on BioShares Biotechnology correlated with the market. If Beta is less then 0 BioShares Biotechnology generally moves in the opposite direction as compared to the market. If BioShares Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one BioShares Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of BioShares Biotechnology is generally in the same direction as the market. If Beta > 1 BioShares Biotechnology moves generally in the same direction as, but more than the movement of the benchmark. View also all equity analysis or get more info about beta statistic functions indicator.
< 3% 

Chance of Financial Distress

BioShares Biotechnology Clinical Trials has less than 3 (%) percent chance of experiencing financial distress in the next 2 years of operations. More Info


Compare BioShares Biotechnology To Peers
Robert Galusza BioShares ETF Portfolio Manager
Lisa Khatri BioShares ETF Portfolio Manager
Ferian Juwono BioShares ETF Portfolio Manager
Scott Baskind BioShares ETF Portfolio Manager
More Executives

Opportunity Range

January 17, 2018 Opportunity Range